Source: ERS webinar 2021: TB and COVID-19 – a dangerous new combination?
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Giovanni Battista Migliori (Varese (VA), Italy), Alberto García-Basteiro (Maputo, Mozambique). TB and COVID-19 – a dangerous new combination?. ERS webinar 2021: TB and COVID-19 – a dangerous new combination?

Member's Comments

Mani Tiwari - 04.03.2022 03:04
Excellent

Related content which might interest you: Extensively drug resistant tuberculosis (XDR TB) in a high income country: a report of four unrelated cases Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 TB drug resistance in high-incidence countries Source: Eur Respir Mon 2012; 58: 95-110 Year: 2012 Is DOTS-Plus effective and cost-effective? Source: Annual Congress 2007 - PG18 - New challenges in fighting tuberculosis in Europe Year: 2007 Pre-immigration screening process and pulmonary tuberculosis among Ethiopian migrants in Israel Source: Eur Respir J 2008; 32: 413-418 Year: 2008 The WHO strategy for TB control and elimination Source: Eur Respir Mon 2012; 58: 242-253 Year: 2012 TB in migrants Source: Eur Respir Mon 2012; 58: 194-205 Year: 2012 The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009 Do results of T-SPOT.TB assays change during and after treatment of active tuberculosis? Source: Annual Congress 2006 - New methods to diagnose tuberculosis infection Year: 2006 Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones}, Source: Eur Respir J 2012; 40: 814-822 Year: 2012 Prevention of TB in areas of low incidence Source: Eur Respir Mon 2012; 58: 72-83 Year: 2012 Recurrence of tuberculosis in a low-incidence setting Source: Eur Respir J 2009; 33: 160-167 Year: 2009 Are interferon- gamma release assays useful for diagnosing active tuberculosis in a high-burden setting? Source: Eur Respir J 2011; 38: 649-656 Year: 2011 Direct costs of three models for the screening of latent tuberculosis infection Source: Eur Respir J 2006; 28: 45-50 Year: 2006 Challenges and perspectives for improved management of HIV/Mycobacterium tuberculosis co-infection Source: Eur Respir J 2010; 36: 1242-1247 Year: 2010 Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection Source: Eur Respir J 2010; 36: 135-142 Year: 2010 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 Incidence of TB latent infection in health care workers in a low TB prevalence country Source: Annual Congress 2005 - Epidemiology and control of tuberculosis and LTBI Year: 2005 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Pulmonary tuberculosis Source: Respipedia Article Year: 2018